Predicted protein targets (top 19)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CDK4 | P11802 | 4/20 | 0.66 |
| ▸ | CCND1 | P24385 | 3/20 | 0.66 |
| ▸ | SYK | P43405 | 5/20 | 0.64 |
| ▸ | CDK2 | P24941 | 5/20 | 0.62 |
| ▸ | CCNA2 | P20248 | 3/20 | 0.62 |
| ▸ | CCNA1 | P78396 | 2/20 | 0.62 |
| ▸ | STAT6 | P42226 | 2/20 | 0.62 |
| ▸ | BRD4 | O60885 | 2/20 | 0.59 |
| ▸ | PIM1 | P11309 | 1/20 | 0.58 |
| ▸ | TTK | P33981 | 1/20 | 0.58 |
| ▸ | PIM2 | Q9P1W9 | 1/20 | 0.58 |
| ▸ | AURKA | O14965 | 2/20 | 0.58 |
| ▸ | CCND3 | P30281 | 1/20 | 0.58 |
| ▸ | CDK6 | Q00534 | 1/20 | 0.58 |
| ▸ | CSF1R | P07333 | 1/20 | 0.57 |
| ▸ | INSR | P06213 | 1/20 | 0.57 |
| ▸ | ALK | Q9UM73 | 1/20 | 0.57 |
| ▸ | SLC2A1 | P11166 | 1/20 | 0.56 |
| ▸ | CDK1 | P06493 | 1/20 | 0.55 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4494580 | 0.90 | SYK (0.56) | CDK4CCND1SYKCDK2CCNA2 | |
| SCHEMBL30962614 | 0.90 | SYK (0.62) | CDK4CCND1SYKCDK2CCNA2 | |
| SCHEMBL4489767 | 0.85 | AXL (0.61) | SYKCDK2CCNA2CCNA1BRD4 | |
| SCHEMBL4504802 | 0.84 | PKMYT1 (0.62) | ALKSLC2A1 | |
| SCHEMBL265505 | 0.80 | SLC2A1 (0.66) | CDK4CCND1SYKCDK2CCNA2 | |
| SCHEMBL4348983 | 0.79 | CDK4 (1.00) | CDK4CCND1SYKCDK2CCNA2 | |
| SCHEMBL4498499 | 0.78 | LCK (0.67) | CDK4CCND1SYKCDK2STAT6 | |
| SCHEMBL735871 | 0.78 | SYK (1.00) | SYK | |
| SCHEMBL4492001 | 0.77 | SYK (0.62) | CDK4CCND1SYKCDK2CCNA2 | |
| SCHEMBL31612065 | 0.77 | SRC (0.70) | CDK4CCND1SYKBRD4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7504396-B2 | Substituted heterocyclic compounds and methods of use | AMGEN INC. (US) | 2009-03-17 | — | — | US | disclosed |
| EP-1648464-A1 | 2-AMINO-4-HYDROXY-5-PYRIMIDINCARBOXAMID DERIVATIVES AND RELATED COMPOUNDS AS T-CELL ACTIVATION INHIBITORS FOR THE TREATMENT OF INFLAMMATIONS | AMGEN INC. (US) | 2006-04-26 | — | — | EP | disclosed |
| US-20050209221-A1 | Substituted heterocyclic compounds and methods of use | AMGEN INC. | 2005-09-22 | — | — | US | disclosed |
| WO-2005009443-A1 | 2-AMINO-4-HYDROXY-5-PYRIMIDINECARBOXAMIDE DERIVATIVES AND RELATED COMPOUNDS AS INHIBITORS OF T CELL ACTIVATION FOR THE TREATMENT OF INFLAMMATORY DISEASES | AMGEN INC. (US) | 2005-02-03 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050209221-A1 | Substituted heterocyclic compounds and methods of use | ICOS, CD4, HLA-DRB1 | CDK4 457/4885CCND1 1265/4885SYK 1151/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.